Frankfurt
22.01.26 | 08:16
1,108 Euro
-0,89 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | DIAMYD MEDICAL AB: Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial | 4 | Cision News | ||
| 12.01. | Diamyd Medical AB (publ): Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial | 97 | GlobeNewswire (Europe) | Diamyd Medical today announced that the screening period in its pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals with type 1 diabetes has been completed. Based on the... ► Artikel lesen | |
| 09.01. | DIAMYD MEDICAL AB: Diamyd Medical's lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein | 4 | Cision News | ||
| 09.01. | Diamyd Medical AB (publ): Diamyd Medical's lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein | 101 | GlobeNewswire (Europe) | Diamyd Medical today announced that its investigational antigen-specific immunotherapy for type 1 diabetes, commonly referred to as Diamyd, has been assigned the global non-proprietary name "retogatein"... ► Artikel lesen | |
| 29.12.25 | Diamyd Medical Secures FDA Alignment To Accelerate Phase 3 Trial Readout In Type 1 Diabetes | 1 | RTTNews | ||
| 29.12.25 | Diamyd Medical AB: Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance | 309 | PR Newswire | STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal... ► Artikel lesen | |
| 12.12.25 | Diamyd Medical AB (publ): Diamyd Medical finalizing Phase 3 screening as GMP review progresses | 150 | GlobeNewswire (Europe) | The number of randomized participants in DIAGNODE-3, Diamyd Medical's registrational Phase 3 trial in type 1 diabetes, has now exceeded 290, and the screening will conclude in the coming weeks. The... ► Artikel lesen | |
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| 02.12.25 | DIAMYD MEDICAL AB: Annual Report 2024/2025 | 5 | Cision News | ||
| 14.11.25 | Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026 | 593 | PR Newswire | STOCKHOLM, Nov. 14, 2025 /PRNewswire/ -- The independent Data Safety Monitoring Board (DSMB) has completed its sixth scheduled safety review of Diamyd Medical's registrational Phase... ► Artikel lesen | |
| 13.11.25 | Diamyd Medical AB Ser. B Full Year Sales Decline | 1 | RTTNews | ||
| 13.11.25 | DIAMYD MEDICAL AB: Information about the Annual Report 2024/2025 | 1 | Cision News | ||
| 12.11.25 | DIAMYD MEDICAL AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment | 3 | Cision News | ||
| 08.10.25 | Diamyd Medical AB Ser. B Q4 Loss Widens | - | RTTNews | ||
| 08.10.25 | DIAMYD MEDICAL AB: Year-End Report 24/25 | 1 | Cision News | ||
| 08.10.25 | Diamyd Medical AB (publ): Year-End Report 24/25 | 242 | GlobeNewswire (Europe) | September 2024 - August 2025, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Type 1 Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen | |
| 03.10.25 | DIAMYD MEDICAL AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 1 | Cision News | ||
| 03.10.25 | Diamyd Medical AB (publ): Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 174 | GlobeNewswire (Europe) | Diamyd Medical has been granted a patent in Hong Kong protecting the use of insulin-based antigens to treat individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker. The patent is valid... ► Artikel lesen | |
| 11.09.25 | DIAMYD MEDICAL AB: New analysis to be presented at EASD supports potential of Diamyd to delay the progression of Stage 3 Type 1 Diabetes | 2 | Cision News | ||
| 10.09.25 | DIAMYD MEDICAL AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 2 | Cision News |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 52,92 | +4,13 % | Aktie zieht kräftig an!: Wegovy-Pille ist da: Milliardenchance für Novo Nordisk - und für Anleger? | © Foto: Christian Schultz/dpaDie Abnehmrevolution gibt es jetzt auch in Tablettenform - und sie könnte sich für Novo Nordisk auszahlen. Nach Einschätzung von Berenberg Research ist die neue Wegovy-Pille... ► Artikel lesen | |
| PFIZER | 22,210 | +0,20 % | Pfizer: Die beste Pharma-Aktie 2026? | Die Aktie von Pfizer gewinnt wieder an Dynamik und rückt damit verstärkt in das Blickfeld langfristig orientierter Anleger. Angesichts einer attraktiven Bewertung, operativer Fortschritte und einer... ► Artikel lesen | |
| ABBVIE | 185,80 | +0,43 % | Dividendenbekanntmachungen (16.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBVIE INC US00287Y1091 1,73 USD 1,4902 EUR ABBVIE INC CDR CA00288K1084 0,2439 CAD 0,1512 EUR ALAMO GROUP INC US0113111076 0... ► Artikel lesen | |
| ABBOTT LABORATORIES | 92,94 | -10,08 % | Dividendenbekanntmachungen (15.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AB DYNAMICS PLC GB00B9GQVG73 0,0636 GBP 0,0734 EUR ABBOTT LABORATORIES US0028241000 0,63 USD 0,541 EUR ABBOTT LABORATORIES CDR CA0028221046 0... ► Artikel lesen | |
| ZOETIS | 106,22 | +1,10 % | Dividendenbekanntmachungen (20.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BLACKROCK CAPITAL ALLOCATION TERM TRUST US09260U1097 0,2607 USD 0,2238 EUR BLACKROCK ENHANCED GLOBAL DIVIDEND TRUST US0925011050 0... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 159,05 | -1,73 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia | NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today... ► Artikel lesen | |
| DAIICHI SANKYO | 16,905 | -2,51 % | Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe | Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe.
Dr. Jürgen Müller will retire after nearly... ► Artikel lesen | |
| TRULIEVE CANNABIS | 7,020 | +1,59 % | Trulieve Cannabis Corp.: Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026 | TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 23,310 | +1,48 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,700 | +0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 68,64 | +2,66 % | BridgeBio Pharma, Inc.: BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 | The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturityOffering priced at 0.75% interest rate and 45% conversion premium PALO ALTO... ► Artikel lesen | |
| TG THERAPEUTICS | 26,915 | -0,44 % | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 12,765 | +1,92 % | Wachstumssorgen: Leerink Partners stuft Aurinia Pharmaceuticals herab | ||
| CAMURUS | 65,50 | +4,22 % | AKTIONÄR-Tipp Camurus: "Top-Pick" - mit Eli Lilly in neue Dimensionen | Die Aktie des schwedischen Biotech-Unternehmens Camurus hat sich in den zurückliegenden Monaten sehr volatil entwickelt. Die Analysten von ABG Sundal Collier (ABGSC) trauen dem Papier allerdings neue... ► Artikel lesen |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,108 Euro und damit -0,89 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.